In this issue of Cancer Cell, Lionakis et al. demonstrate that the combination of temozolomide, etoposide, doxorubicin, dexamethasone, rituximab, and the Bruton tyrosine kinase (BTK) inhibitor ibrutinib induced frequent responses in patients with primary central nervous system lymphoma but was associated with significant toxicity, including pulmonary and cerebral aspergillosis infections.
CITATION STYLE
Grommes, C., & Younes, A. (2017, June 12). Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. Cancer Cell. Cell Press. https://doi.org/10.1016/j.ccell.2017.05.004
Mendeley helps you to discover research relevant for your work.